Atara Biotherapeutics Inc ATRA.OQ ATRA.O is expected to show a rise in quarterly revenue when it reports results on November 12 for the period ending September 30 2024
The Thousand Oaks California-based company is expected to report a 1,544.9% increase in revenue to $35.168 million from $2.14 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Atara Biotherapeutics Inc is for a loss of $1.93 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Atara Biotherapeutics Inc is $14.00, above its last closing price of $10.10.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -1.38 | -1.56 | -3.10 | Missed | -98.4 |
Mar. 31 2024 | -6.17 | -6.41 | -5.75 | Beat | 10.3 |
Dec. 31 2023 | -7.75 | -12.05 | -14.00 | Missed | -16.2 |
Sep. 30 2023 | -16.57 | -16.55 | -16.50 | Beat | 0.3 |
Jun. 30 2023 | -16.58 | -16.81 | -17.00 | Missed | -1.1 |
Mar. 31 2023 | -9.39 | -9.79 | -18.00 | Missed | -83.8 |
Dec. 31 2022 | -12.29 | -12.69 | -18.00 | Missed | -41.8 |
Sep. 30 2022 | -19.24 | -19.62 | -20.50 | Missed | -4.5 |
This summary was machine generated November 8 at 23:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。